Aptose Non Current Assets Total vs Total Stockholder Equity Analysis
APTO Stock | USD 0.39 0.02 5.41% |
Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Non Current Assets Total and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.
Non Current Assets Total vs Total Stockholder Equity
Non Current Assets Total vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Non Current Assets Total account and Total Stockholder Equity. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Aptose Biosciences' Non Current Assets Total and Total Stockholder Equity is 0.46. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Non Current Assets Total and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Aptose Biosciences are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Non Current Assets Total i.e., Aptose Biosciences' Non Current Assets Total and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.46 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 31st of October 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 5.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 94K | 788K | 1.4M | 1.5M | Interest Income | 94K | 788K | 1.4M | 1.5M |
Aptose Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Aptose Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptose Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.5M | 126.3M | 82.5M | 51.0M | 12.9M | 12.3M | |
Other Current Liab | 3.1M | 4.1M | 6.0M | 5.7M | 13.9M | 14.6M | |
Total Current Liabilities | 5.5M | 6.8M | 8.2M | 12.3M | 15.2M | 16.0M | |
Total Stockholder Equity | 93.9M | 118.9M | 74.2M | 37.7M | (2.9M) | (2.7M) | |
Property Plant And Equipment Net | 1.7M | 1.2M | 788K | 1.5M | 1.1M | 574.3K | |
Net Debt | (78.3M) | (116.3M) | (38.5M) | (35.7M) | (8.2M) | (8.6M) | |
Retained Earnings | (301.9M) | (357.2M) | (422.5M) | (464.3M) | (512.9M) | (487.3M) | |
Accounts Payable | 2.0M | 2.2M | 1.7M | 6.3M | 3.5M | 3.7M | |
Cash | 79.8M | 117.4M | 39.1M | 37.0M | 9.2M | 15.8M | |
Non Current Assets Total | 1.7M | 1.2M | 788K | 1.5M | 1.1M | 1.7M | |
Cash And Short Term Investments | 97.6M | 122.4M | 79.1M | 47.0M | 9.2M | 8.7M | |
Common Stock Shares Outstanding | 3.3M | 5.5M | 5.9M | 6.2M | 6.8M | 7.1M | |
Short Term Investments | 798K | 440K | 17.8M | 5M | 40.0M | 10.0M | |
Liabilities And Stockholders Equity | 100.5M | 126.3M | 82.5M | 51.0M | 12.9M | 12.3M | |
Non Current Liabilities Total | 1.0M | 535K | 115K | 1.0M | 617.8K | 586.9K | |
Other Current Assets | 141K | 129K | 133K | 257K | 2.6M | 2.8M | |
Other Stockholder Equity | 34.6M | 50.9M | 63.7M | 68.9M | 71.8M | 75.4M | |
Total Liab | 6.6M | 7.3M | 8.3M | 13.3M | 15.8M | 16.6M | |
Property Plant And Equipment Gross | 1.7M | 1.2M | 323K | 211K | 3.9M | 4.1M | |
Total Current Assets | 98.8M | 125.1M | 81.7M | 49.5M | 11.8M | 11.2M | |
Non Currrent Assets Other | (94.0) | (48.0) | 465K | 1.3M | 1.2M | 1.2M | |
Intangible Assets | 1.0 | 142.0 | 94.0 | 48.0 | 43.2 | 41.04 | |
Net Tangible Assets | 93.8M | 118.9M | 74.2M | 37.7M | 43.4M | 45.6M | |
Common Stock Total Equity | 365.5M | 429.5M | 437.4M | 437.5M | 503.1M | 528.3M | |
Retained Earnings Total Equity | (301.9M) | (357.2M) | (422.5M) | (464.3M) | (417.9M) | (397.0M) | |
Common Stock | 365.5M | 429.5M | 437.4M | 437.5M | 442.5M | 231.4M | |
Property Plant Equipment | 1.6M | 1.1M | 788K | 211K | 189.9K | 364.1K | |
Capital Surpluse | 34.6M | 50.9M | 63.7M | 68.9M | 79.2M | 51.4M | |
Net Invested Capital | 93.9M | 118.9M | 74.2M | 37.7M | (2.9M) | (2.8M) | |
Net Working Capital | 93.2M | 118.3M | 73.6M | 37.2M | (3.4M) | (3.2M) | |
Capital Stock | 365.5M | 429.5M | 437.4M | 437.5M | 444.8M | 435.6M |
Pair Trading with Aptose Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptose Stock
Moving against Aptose Stock
0.56 | BMY | Bristol Myers Squibb | PairCorr |
0.52 | MLYS | Mineralys Therapeutics, | PairCorr |
0.51 | FLGC | Flora Growth Corp | PairCorr |
0.5 | EWTX | Edgewise Therapeutics | PairCorr |
0.36 | EXEL | Exelixis Upward Rally | PairCorr |
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.24) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.